Pandemic Influenza Therapeutic Pipeline Review H1 2015 Research Report

DALLAS, March 24, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Pandemic Influenza - Pipeline Review, H1 2015" therapeutic market research report of 135 pages with latest updates, data and information to its online business intelligence library.

The report "Pandemic Influenza - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Pandemic Influenza. An influenza pandemic can occur when a non-human (novel) influenza virus gains the ability for efficient and sustained human-to-human transmission and then spreads globally. A pandemic is a global disease outbreak. It is determined by how the disease spreads not how many deaths it causes. A worldwide influenza pandemic could have a major effect on the global economy, including travel, trade, tourism, food, consumption and eventually, investment and financial markets. Planning for pandemic influenza by business and industry is essential to minimize a pandemic's impact. It is difficult to predict when the next influenza pandemic will occur or how severe it will be.

The report also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. Companies discussed in this report include AIMM Therapeutics B.V., AltraVax Inc., AmVac AG, Big DNA Ltd., BioDiem Ltd, Celltrion, Inc., Cilian AG, Codagenix, Inc., ContraFect Corporation, Emergent BioSolutions Inc., GlaxoSmithKline plc, Hemispherx Biopharma, Inc., Immunovaccine, Inc., Johnson & Johnson, Medicago Inc., NanoBio Corporation, Novartis AG, Novavax, Inc., OPKO Health, Inc., PDS Biotechnology Corporation, PeptiVir, Inc., Protein Sciences Corporation, Sinovac Biotech Ltd., Sirnaomics, Inc., TaiGen Biotechnology Co., Ltd., TechnoVax, Inc., Theraclone Sciences, Inc., TSRL, Inc., UMN Pharma Inc., VaxInnate Corporation.

Drug Profiles discussed in this report include A-06, Alferon LDO, AMV-411, BDNA-002, Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza, CF-404, CiFlu, CTP-25, CTP-27, flu pandemic (H5N1) vaccine, IKT-041, influenza (H5) vaccine, influenza [H7N9] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant, influenza [strain H5N1] (monovalent) vaccine, influenza [strain H7N9] (monovalent) vaccine, influenza vaccine, Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza, Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza, Monoclonal Antibody to Inhibit Hemagglutinin for Influenza, MVAH-5HA, pandemic infleunza vaccine, pandemic influenza [H5N1] vaccine, PDS-0102, PVI-1000, Small Molecules for Influenza, STP-702, TCN-032, TSR-026, TSR-462, TVX-002, UMN-0501, UMN-0901, VAX-161, VAX-16101C, VX-787. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310135 . (This is a premium report priced at US$2000 for a single user License.)

The scope of the report ranges from global therapeutic landscape of Pandemic Influenza to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Pandemic Vaccine at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/pandemic-vaccine .

More reports on Infectious Diseases Therapeutics Market:

Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Arenavirus Infection Lassa Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Profectus BioSciences, Inc., SIGA Technologies, Inc. Complete report available at http://www.rnrmarketresearch.com/arenavirus-infection-lassa-fever-pipeline-review-h1-2015-market-report.html .

Plague - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Plague. Companies discussed in this report include Aradigm Corporation, Cellceutix Corporation, Grifols, S.A., iBio, Inc., Mucosis B.V., Summit Corporation plc, Syntiron LLC, Tetraphase Pharmaceuticals Inc. Complete report available at http://www.rnrmarketresearch.com/plague-pipeline-review-h1-2015-market-report.html .

Smallpox - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Smallpox. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Companies discussed in this report AlphaVax, Inc., Bavarian Nordic A/S, CEL-SCI Corporation, Chimerix, Inc., CJ CheilJedang Corp., EpiVax, Inc., Inovio Pharmaceuticals, Inc., MacroGenics, Inc., Nanotherapeutics, Inc., Oncovir, Inc., SIGA Technologies, Inc., Symphogen A/S, TapImmune Inc., Tonix Pharmaceuticals Holding Corp. Complete report available at http://www.rnrmarketresearch.com/smallpox-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com